Toxic erythema of chemotherapy induced by liposomal doxorubicin, a clinical case

A 76-year-old woman presented to the medical oncology outpatient clinic with painful, burning, pruritic erythematous plaques involving both palms and axillae that had suddenly appeared five days before. Examination revealed no additional relevant findings and laboratory studies did not show any alte...

Full description

Saved in:
Bibliographic Details
Published in:Dermatology online journal 2022-01, Vol.28 (1)
Main Authors: Esperanca-Martins, Miguel, Lobo-Martins, Soraia, Sanches, Maria, Brazao, Claudia, Pena, Barbara, Correia, Catarina, Aguado-Lobo, Marta, Espinosa-Lara, Pablo, Costa, Luis, Soares-de-Almeida, Luis, Fernandes, Isabel
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Agents
Chemotherapy
Dermatology
Doxorubicin - adverse effects
Doxorubicin - analogs & derivatives
Erythema - chemically induced
Female
Hemangiosarcoma
Humans
Polyethylene Glycols
Skin diseases
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 76-year-old woman presented to the medical oncology outpatient clinic with painful, burning, pruritic erythematous plaques involving both palms and axillae that had suddenly appeared five days before. Examination revealed no additional relevant findings and laboratory studies did not show any alteration. The patient had been recently diagnosed with a high-grade angiosarcoma of the breast (probably radiation induced) and after frequent local recurrences, was being treated with liposomal doxorubicin (three cycles were administered, the last of which was seven days before the appearance of the mentioned lesions). Oral corticosteroids were started, treatment with liposomal doxorubicin was stopped, and cutaneous biopsies performed that revealed features compatible with toxic erythema of chemotherapy induced by liposomal doxorubicin. Complete resolution of the cutaneous lesions was verified one month after. No signs of recurrence of angiosarcoma were documented at follow-up three months later.
ISSN:1087-2108
1087-2108
DOI:10.5070/D328157060